Boston Scientific (BSX) Non-Current Deferred Tax Liability (2009 - 2026)

Boston Scientific has disclosed Non-Current Deferred Tax Liability across 18 years of filings, most recently posting $221.0 million for Q2 2026.

• In Q2 2026, Non-Current Deferred Tax Liability fell 2.21% year-over-year to $221.0 million; the TTM figure through Jun 2026 stood at $221.0 million (down 2.21% YoY), while the FY2025 annual figure was $220.0 million, down 0.9% from the prior year.
• Non-Current Deferred Tax Liability came in at $221.0 million for Q2 2026 at Boston Scientific, up from $219.0 million in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $278.0 million in Q3 2022 to a low of $91.0 million in Q3 2023.
• Average Non-Current Deferred Tax Liability over 5 years is $190.8 million, with a median of $214.5 million recorded in 2023.
• Year-over-year, Non-Current Deferred Tax Liability surged 130.43% in 2022 and sank 67.27% in 2023.
• Over 5 years, Non-Current Deferred Tax Liability stood at $151.0 million in 2022, then dropped by 11.26% to $134.0 million in 2023, then jumped by 65.67% to $222.0 million in 2024, then dropped by 0.9% to $220.0 million in 2025, then advanced by 0.45% to $221.0 million in 2026.
• Per Business Quant data, the three most recent Non-Current Deferred Tax Liability figures were $221.0 million in Q2 2026, $219.0 million in Q1 2026, and $220.0 million in Q4 2025.